echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Development of a new indication for dimethyl fumarate: Sword finger diffuse large B-cell lymphoma

    Development of a new indication for dimethyl fumarate: Sword finger diffuse large B-cell lymphoma

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Author: Yuntian

    Dimethyl Fumarate (DMF, trade name Tecfidera) is an oral relapsing multiple sclerosis drug developed by Biogen Idec


    Figure 1.


    First, the researchers found through cell inhibition experiments that dimethyl fumarate has a significant inhibitory effect on a variety of B-cell lymphoma cells, but has no inhibitory effect on other tumor cells such as K562 and U937.


    Figure 2 Inhibitory effect of dimethyl fumarate on human diffuse B-cell lymphoma cells

    Figure 3 The inhibitory effect of dimethyl fumarate on other tumor cells

    Further research found that the main mechanism of action of dimethyl fumarate against diffuse B-cell lymphoma is to promote iron death through the GSH-Gpx4 pathway


    Figure 4 GSH consumption experiment

    In addition, the researchers found through experiments that dimethyl fumarate may exert an anti-tumor effect through the STAT3 pathway.


    Figure 5.


    Diffuse large B-cell lymphoma is a common clinical lymphoma


    For the treatment of patients with diffuse large B-cell lymphoma, compared with the past, the current use of rituximab therapy can give patients greater benefits, but the effect is still limited


    Note: The original text has been deleted

    references:

    1.


    2.


    3.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.